Cargando…

High incidence and reversible bradycardia events following alectinib initiation

BACKGROUND: With the widespread use of alectinib in patients with anaplastic lymphoma kinase (ALK)‐positive non‐small‐cell lung cancer (NSCLC), its cardiotoxicity has gradually emerged, including new‐onset sinus bradycardia (SB). However, the incidence, timing, severity, and risk factors of alectini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Dongqi, Zhu, Fuyi, Zuo, Ran, Wang, Yu, Huo, Gengwei, Cui, Jinfang, Yue, Ping, Chen, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925342/ https://www.ncbi.nlm.nih.gov/pubmed/36535917 http://dx.doi.org/10.1111/1759-7714.14769

Ejemplares similares

Significance of Alectinib-Induced Bradycardia: Rhythm and Reversibility Matter More Than Rate
por: Kondapalli, Lavanya, et al.
Publicado: (2023)

A Pan-Cancer Analysis of the Oncogenic Role of Twinfilin Actin Binding Protein 1 in Human Tumors
por: Huo, Gengwei, et al.
Publicado: (2021)

Inetetamab, a novel anti-HER2 monoclonal antibody, exhibits potent synergistic anticancer effects with cisplatin by inducing pyroptosis in lung adenocarcinoma
por: Cui, Jinfang, et al.
Publicado: (2023)

The response prediction and prognostic values of systemic inflammation response index in patients with advanced lung adenocarcinoma
por: Zuo, Ran, et al.
Publicado: (2023)

A Rare but Reversible Cause of Lithium-Induced Bradycardia
por: Ataallah, Basma, et al.
Publicado: (2020)

SINUS BRADYCARDIA AS THE INITIAL MANIFESTATION OF COVID-19
por: Mendoza, Ivan, et al.
Publicado: (2021)

Fetal Circulatory Variation in an Acute Incident Causing Bradycardia
por: Olgan, Safak, et al.
Publicado: (2014)

Bradycardia
por: Gibson, G. A.
Publicado: (1905)

Bradycardia
por: Gibson, G. A.
Publicado: (1905)

Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature
por: Ramachandran, P, et al.
Publicado: (2018)

Paradoxical worsening of bradycardia following atropine administration
por: Armour, Richard, et al.
Publicado: (2022)

Sinus bradycardia as the initial manifestation of multisystem inflammatory syndrome in children
por: Gonzalez, K, et al.
Publicado: (2021)

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
por: Morcos, Peter N., et al.
Publicado: (2018)

Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features
por: Huo, Gengwei, et al.
Publicado: (2022)

Oncogenic role of TWF2 in human tumors: A pan-cancer analysis
por: Liu, Wenjie, et al.
Publicado: (2022)

Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis
por: Liu, Wenjie, et al.
Publicado: (2022)

Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis
por: Huo, Gengwei, et al.
Publicado: (2023)

Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics
por: Liu, Wenjie, et al.
Publicado: (2023)

First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States
por: Liu, Wenjie, et al.
Publicado: (2023)

Atrial Bradycardia
por: Shaw, David B., et al.
Publicado: (1969)

Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer
por: Kimura, Tatsuo, et al.
Publicado: (2016)

Burden of bradycardia and barriers to accessing bradycardia therapy in underserved countries
por: Egas, Diego, et al.
Publicado: (2023)

Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC
por: Peng, Ling, et al.
Publicado: (2021)

Metabolites of alectinib in human: their identification and pharmacological activity
por: Sato-Nakai, Mika, et al.
Publicado: (2017)

Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis
por: Huo, Gengwei, et al.
Publicado: (2023)

First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis
por: Liu, Wenjie, et al.
Publicado: (2023)

Case report: severe bradycardia, a reversible cause of “Cardio-Renal-Cerebral Syndrome”
por: Aoun, Mabel, et al.
Publicado: (2016)

Dengue and Relative Bradycardia
por: Senanayake, Sanjaya Naresh
Publicado: (2008)

Dengue and Relative Bradycardia
por: Lateef, Aisha, et al.
Publicado: (2007)

Haemodynamic bradycardia in tachycardiomyopathy
por: Mafirad, M., et al.
Publicado: (2011)

A Case of Bradycardia
por: Pancholy, K. J.
Publicado: (1931)

Mesalamine Associated Bradycardia
por: Krzyzak, Michael, et al.
Publicado: (2018)

Bradycardia in Maxillofacial Surgery
por: Aggarwal, Krittika, et al.
Publicado: (2020)

Remdesivir-associated bradycardia
por: Ching, Patrick R, et al.
Publicado: (2021)

Azithromycin-Induced Bradycardia
por: Abdelazeem, Basel, et al.
Publicado: (2021)

Postoperative bradycardia following bladder exstrophy surgery: An anesthesiologist's nightmare
por: Kumar, Amarjeet, et al.
Publicado: (2021)

Progressive renal insufficiency related to ALK inhibitor, alectinib
por: Nagai, Kojiro, et al.
Publicado: (2018)

Development of Alectinib-Suspended SNEDDS for Enhanced Solubility and Dissolution
por: Park, Eun Ji, et al.
Publicado: (2022)

Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up
por: Pruis, Melinda A., et al.
Publicado: (2023)

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
por: Watanabe, Satoshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dk5v4pphr7vdlgmqhac649du2h